Artificial Intelligence for Drug Development

Why It Matters

Standardizing AI oversight accelerates drug development while safeguarding efficacy and safety, positioning the U.S. as a leader in regulated AI‑driven therapeutics.

Key Takeaways

• FDA received over 800 comments on AI discussion paper since 2023.
• CDER AI Council formed 2024 to unify AI policy and oversight.
• Over 500 AI‑enabled drug submissions reviewed by CDER between 2016‑2023.
• Guiding principles with EMA aim to standardize global AI use in drugs.

Pulse Analysis

Artificial intelligence is reshaping every stage of drug development, from target discovery to post‑marketing surveillance. The FDA’s CDER recognizes this shift, publishing a 2025 draft guidance that outlines how AI‑generated data can support regulatory decisions on safety, efficacy, and quality. By cataloguing more than 500 AI‑infused submissions over the past seven years, CDER demonstrates both the growing reliance on machine‑learning models and the need for clear, risk‑based criteria that protect patients while encouraging innovation.

To streamline governance, CDER launched an AI Council in 2024, consolidating earlier working groups and steering internal talent, technology, and policy initiatives. The Council serves as a single point of contact for sponsors, ensuring consistent communication and aligning CDER’s AI activities with broader FDA and HHS objectives. This centralized approach also prepares the agency for emerging technologies such as generative AI and large language models, which promise to democratize data analysis across both technical and non‑technical staff.

International coordination is another pillar of CDER’s strategy. Jointly with the European Medicines Agency, the agency co‑authored ten guiding principles that aim to harmonize AI practices across borders, reducing regulatory fragmentation for multinational developers. These principles, coupled with CDER’s own guidance documents, create a roadmap for industry to responsibly integrate AI, ultimately shortening development timelines, lowering costs, and delivering safer, more effective therapies to patients worldwide.